Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.

Rabl R, Breitschaedel C, Flunkert S, Duller S, Amschl D, Neddens J, Niederkofler V, Rockenstein E, Masliah E, Roemer H, Hutter-Paier B.

BMC Neurosci. 2017 Jan 31;18(1):22. doi: 10.1186/s12868-017-0341-8.

2.

Effects of decreased dopamine transporter levels on nigrostriatal neurons and paraquat/maneb toxicity in mice.

Richter F, Gabby L, McDowell KA, Mulligan CK, De La Rosa K, Sioshansi PC, Mortazavi F, Cely I, Ackerson LC, Tsan L, Murphy NP, Maidment NT, Chesselet MF.

Neurobiol Aging. 2017 Mar;51:54-66. doi: 10.1016/j.neurobiolaging.2016.11.015.

PMID:
28038352
3.

Alpha-synuclein modulates dopamine neurotransmission.

Butler B, Sambo D, Khoshbouei H.

J Chem Neuroanat. 2016 Jun 19. pii: S0891-0618(16)30068-0. doi: 10.1016/j.jchemneu.2016.06.001. [Epub ahead of print] Review.

PMID:
27334403
4.

How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Volpicelli-Daley LA, Kirik D, Stoyka LE, Standaert DG, Harms AS.

J Neurochem. 2016 Oct;139 Suppl 1:131-155. doi: 10.1111/jnc.13627. Review.

PMID:
27018978
5.

Dopamine Transporter Activity Is Modulated by α-Synuclein.

Butler B, Saha K, Rana T, Becker JP, Sambo D, Davari P, Goodwin JS, Khoshbouei H.

J Biol Chem. 2015 Dec 4;290(49):29542-54. doi: 10.1074/jbc.M115.691592.

6.

Raft-partitioning of calcium channels regulates their function.

Ronzitti G, Bucci G, Stephens G, Chieregatti E.

Channels (Austin). 2015;9(4):169-70. doi: 10.1080/19336950.2015.1063285. No abstract available.

7.

The temporal expression pattern of alpha-synuclein modulates olfactory neurogenesis in transgenic mice.

Schreglmann SR, Regensburger M, Rockenstein E, Masliah E, Xiang W, Winkler J, Winner B.

PLoS One. 2015 May 11;10(5):e0126261. doi: 10.1371/journal.pone.0126261.

8.
9.

Parkinson's disease: animal models and dopaminergic cell vulnerability.

Blesa J, Przedborski S.

Front Neuroanat. 2014 Dec 15;8:155. doi: 10.3389/fnana.2014.00155. Review.

10.

Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein.

Magen I, Ostritsky R, Richter F, Zhu C, Fleming SM, Lemesre V, Stewart AJ, Morimoto BH, Gozes I, Chesselet MF.

Pharmacol Res Perspect. 2014 Oct;2(5):e00065. doi: 10.1002/prp2.65.

11.

Microdialysis in the rat striatum: effects of 24 h dexamethasone retrodialysis on evoked dopamine release and penetration injury.

Nesbitt KM, Varner EL, Jaquins-Gerstl A, Michael AC.

ACS Chem Neurosci. 2015 Jan 21;6(1):163-73. doi: 10.1021/cn500257x.

12.

Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.

Longo F, Russo I, Shimshek DR, Greggio E, Morari M.

Neurobiol Dis. 2014 Nov;71:62-73. doi: 10.1016/j.nbd.2014.07.013.

13.

A GCase chaperone improves motor function in a mouse model of synucleinopathy.

Richter F, Fleming SM, Watson M, Lemesre V, Pellegrino L, Ranes B, Zhu C, Mortazavi F, Mulligan CK, Sioshansi PC, Hean S, De La Rosa K, Khanna R, Flanagan J, Lockhart DJ, Wustman BA, Clark SW, Chesselet MF.

Neurotherapeutics. 2014 Oct;11(4):840-56. doi: 10.1007/s13311-014-0294-x.

14.

Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast.

Grosso H, Woo JM, Lee KW, Im JY, Masliah E, Junn E, Mouradian MM.

FASEB J. 2014 Oct;28(10):4280-91. doi: 10.1096/fj.14-251413.

15.

Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.

Liu G, Yu J, Ding J, Xie C, Sun L, Rudenko I, Zheng W, Sastry N, Luo J, Rudow G, Troncoso JC, Cai H.

J Clin Invest. 2014 Jul;124(7):3032-46. doi: 10.1172/JCI72176.

16.

Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.

Richter F, Gao F, Medvedeva V, Lee P, Bove N, Fleming SM, Michaud M, Lemesre V, Patassini S, De La Rosa K, Mulligan CK, Sioshansi PC, Zhu C, Coppola G, Bordet T, Pruss RM, Chesselet MF.

Neurobiol Dis. 2014 Sep;69:263-75. doi: 10.1016/j.nbd.2014.05.012.

17.

Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease.

Grant LM, Richter F, Miller JE, White SA, Fox CM, Zhu C, Chesselet MF, Ciucci MR.

Behav Neurosci. 2014 Apr;128(2):110-21. doi: 10.1037/a0035965.

18.

Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD.

Nuber S, Tadros D, Fields J, Overk CR, Ettle B, Kosberg K, Mante M, Rockenstein E, Trejo M, Masliah E.

Acta Neuropathol. 2014 Apr;127(4):477-94. doi: 10.1007/s00401-014-1255-5.

19.

Animal models of Parkinson's disease: a gateway to therapeutics?

Le W, Sayana P, Jankovic J.

Neurotherapeutics. 2014 Jan;11(1):92-110. doi: 10.1007/s13311-013-0234-1. Review.

20.
Items per page

Supplemental Content

Support Center